Date: 2011-04-26
Type of information: Licensing agreement
Compound: KUR-111, KUR-113, KUR-115
Company: Kuros Biosurgery (Switzerland) Baxter (USA)
Therapeutic area: Traumatology
Type agreement: licensing
Action mechanism: trauma and spine product candidates
Disease:
Details: Kuros Biosurgery has regained rights to a number of trauma and spine product candidates that were previously licensed to Baxter International Inc. Kuros’ regained rights include the following product candidates:
• KUR-111 – KUR-111 has met its primary efficacy endpoint demonstrating non-inferiority to autograft in a 183 patient Phase II study in tibial plateau fracture patients.
• KUR-113 - KUR-113 is in an ongoing Phase II study evaluating the efficacy and safety of KUR-113 as an adjunct to the standard of care in the treatment of patients with acute open tibial shaft fractures.
• KUR-115 – which is being prepared for clinical studies in spinal fusion patients.
Baxter and Kuros continue to be partners in the development of KUR-211, a product for the treatment of chronic wounds which is currently in a large pan European Phase II study involving patients with diabetic foot ulcers.
Kuros and Baxter International Inc. signed their original collaboration and license agreement in 2005.
Financial terms:
Latest news:
